NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue:
Renal Disease Treatments: Products and Therapies
Advertisement
http://www.reportlinker.com/p0166824/Renal-Disease-Treatments-Products-and-Therapies.html
Forecasts for the U.S. market in products and services, providing data for 2008 and estimates for 2009, and projections for the market and compound annual growth rates (CAGRs) from 2009 to 2014
Advertisement
Focus on pharmaceutical products, dialysis therapies, and surgical procedures in the U.S. market for renal failure treatment
Breakdown of the dialysis equipment market by type and manufacturer, and the dialysis services market by provider
Detailed company profiles
Chapter- 1: INTRODUCTION -- Complimentary
STUDY GOAL AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 2
SCOPE OF REPORT 2
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 4
DISCLAIMER 4
Chapter-2: SUMMARY
SUMMARY 5
SUMMARY TABLE THE U.S. MARKET FOR RENAL FAILURE TREATMENT, THROUGH 2014 ($ MILLIONS) 6
SUMMARY FIGURE U.S. MARKET FOR RENAL FAILURE TREATMENT, 1996-2014 ($ MILLIONS) 7
Chapter-3: OVERVIEW
KIDNEY FUNCTION 8
KIDNEY DISEASE 9
TABLE 1 DISEASES LEADING TO RENAL FAILURE 10
DETECTING KIDNEY DISEASE 10
TYPICAL TESTS 10
PATIENT POPULATIONS 11
TABLE 2 ESTIMATED ARF, CKD, AND ESRD POPULATIONS, INCLUDING TRANSPLANT RECIPIENTS AND ROUTINE DIALYSIS PATIENTS, 1996-2009 12
FIGURE 1 ESTIMATED ARF, CKD, AND ESRD POPULATIONS, INCLUDING TRANSPLANT RECIPIENTS AND ROUTINE DIALYSIS PATIENTS, 1996-2009 12
HOSPITALIZATIONS WITH RENAL FAILURE LISTED AS A DIAGNOSIS 12
FIGURE 2 AGE-SPECIFIC HOSPITALIZATION RATES* FOR KIDNEY DISEASE,** BY AGE GROUP -- NATIONAL HOSPITAL DISCHARGE SURVEY, UNITED STATES, 1980-2005 13
FIGURE 3 AGE-ADJUSTED HOSPITALIZATION RATES FOR KIDNEY DISEASE BY TYPE, 1980-2005 14
TABLE 3 NUMBER OF HOSPITALIZATIONS AND AGE-ADJUSTED HOSPITALIZATION RATES FOR KIDNEY DISEASE, BY SEX AND YEAR, NATIONAL HOSPITAL DISCHARGE SURVEY, 1980-2005 15
FIGURE 4 NUMBER OF HOSPITALIZATIONS FOR KIDNEY DISEASE, BY SEX AND YEAR, NATIONAL HOSPITAL DISCHARGE SURVEY, 1980-2005 16
WHO PAYS THE COSTS OF KIDNEY DISEASE? 16
WHAT MEDICARE COVERS 17
MEDICARE'S ESRD PROGRAM 18
Breakdown of ESRD Population by Payer 19
Chapter-4: ACUTE KIDNEY FAILURE
INCIDENCE OF ACUTE KIDNEY FAILURE 20
CAUSES OF ACUTE KIDNEY FAILURE 21
PRERENAL FAILURE 21
RENAL DAMAGE 21
POSTRENAL FAILURE 22
ACUTE KIDNEY FAILURE TREATMENT 23
COSTS OF TREATING ACUTE RENAL FAILURE 23
TABLE 4 BREAKDOWN OF AVERAGE ARF TREATMENT COSTS, BY SUBCATEGORY OF CARE ($) 24
FIGURE 5 BREAKDOWN OF ARF TREATMENT COSTS, BY SUBCATEGORY OF CARE ($) 24
PHARMACEUTICALS 25
FUROSEMIDE 25
DOPAMINE 25
EPINEPHRINE 26
RENAL RELACEMENT THERAPY 26
RESEARCH SUGGESTS NO SUPERIORITY OF RRT MODES IN TREATING ARF 27
THE U.S. MARKET FOR TREATING ACUTE RENAL FAILURE 27
PHARMACEUTICALS IN ARF TREATMENT 28
RRT IN ARF TREATMENT 28
TABLE 5 U.S MARKET FOR ACUTE RENAL FAILURE TREATMENT, THROUGH 2014 ($ MILLION) 29
FIGURE 6 U.S. MARKET FOR ACUTE RENAL FAILURE TREATMENT, 1996-2014 ($ MILLION) 30
Chapter-5: CHRONIC KIDNEY FAILURE
INCIDENCE OF CHRONIC KIDNEY FAILURE 31
CAUSES OF CHRONIC KIDNEY FAILURE 31
TABLE 6 PRIMARY CAUSES OF KIDNEY FAILURE (% OF PATIENTS) 32
FIGURE 7 PRIMARY CAUSES OF KIDNEY FAILURE (% OF PATIENTS) 33
FIGURE 8 CKD PREDICTORS IN THE U.S. POPULATION AGED 20 AND OLDER 34
CKD STAGES 34
TABLE 7 STAGES OF CHRONIC KIDNEY DISEASE 35
STAGE 1 35
STAGE 2 35
STAGE 3 36
STAGE 4 36
STAGE 5 (ESRD) 36
NUMBER OF INDIVIDUALS WITH CKD 37
TABLE 8 PATIENTS WITH CKD AND AWARENESS OF THE DISEASE, BY STAGE, 2009 (NUMBER AND %) 37
FIGURE 9 PATIENTS WITH CKD AND AWARENESS OF THE DISEASE, BY STAGE 2009 (%) 37
CHARACTERISTICS OF THE CKD PATIENT POPULATION 38
TABLE 9 CKD PATIENT CHARACTERISTICS (COLUMN %) 38
TREATMENT GOALS 38
ESRD 39
TABLE 10 ESRD TREATMENT, BY MODALITY (PERCENTAGE AND NUMBER OF PATIENTS) 40
FIGURE 10 ESRD TREATMENT, BY MODALITY (PERCENTAGE OF PATIENTS) 40
TABLE 11 DIALYSIS FOR ESRD, BY TREATMENT MODALITY, 2009 41
FIGURE 11 DIALYSIS FOR ESRD, BY TREATMENT MODALITY, 2009 (%) 41
COSTS OF CHRONIC KIDNEY DISEASE 41
TABLE 12 INPATIENT/OUTPATIENT AND PHYSICIAN /SUPPLIER NET COSTS FOR CKD ($, PER PATIENT PER MONTH, 2006) 42
TABLE 12 (CONTINUED) 43
FIGURE 12 PPPM EXPENDITURES FOR CKD PATIENTS, 1993-2006 (MEDICARE, MEDICARE/MEDICAID, MEDSTAT [EMPLOYER PAID INSURANCE]) 44
THE U.S. MARKET FOR TREATING CHRONIC KIDNEY FAILURE AND END-STAGE RENAL DISEASE 45
TABLE 13 THE U.S. MARKET FOR CKD/ESRD TREATMENT BY TYPE, 1996-2014 ($ MILLION) 46
FIGURE 13 THE U.S. MARKET FOR CHRONIC RENAL FAILURE TREATMENT BY TYPE, 1996-2014 ($ MILLION) 46
Chapter-6: PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT
TABLE 14 PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT BY TYPE AND MANUFACTURER 47
TABLE 14 (CONTINUED) 48
ANTIHYPERTENSIVES 48
ACE INHIBITORS 48
TABLE 15 COMMONLY PRESCRIBED ACE INHIBITORS: BRAND NAME, GENERIC NAME AND MANUFACTURER 49
ANGIOTENSIN RECEPTOR BLOCKERS 49
TABLE 16 COMMONLY PRESCRIBED ANGIOTENSIN RECEPTOR BLOCKERS BRAND NAME, GENERIC NAME AND MANUFACTURER 50
BETA-BLOCKERS 50
TABLE 17 COMMONLY PRESCRIBED BETA BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER 50
CALCIUM CHANNEL BLOCKERS 51
TABLE 18 COMMONLY PRESCRIBED CALCIUM CHANNEL BLOCKERS 51
DIRECT RENIN INHIBITORS 51
CHOLESTEROL MANAGEMENT MEDICATIONS 52
STATINS 52
TABLE 19 COMMONLY PRESCRIBED STATIN DRUGS 53
BILE ACID SEQUESTRANTS 53
TABLE 20 COMMONLY-PRESCRIBED BILE ACID SEQUESTRANTS 53
CHOLESTEROL ABSORPTION INHIBITORS 54
FIBRATES 54
TABLE 21 COMMONLY PRESCRIBED FIBRATES 54
NIACIN 55
COMBINATION MEDICATIONS 55
DIURETICS 55
THIAZIDE DIURETICS 56
LOOP DIURETICS 56
POTASSIUM-SPARING DIURETICS 56
TABLE 22 COMMONLY PRESCRIBED DIURETICS: BRAND NAME, GENERIC NAME, TYPE, AND MANUFACTURER 57
ERYTHROPOIESIS-STIMULATING AGENTS 58
TABLE 23 COMMONLY PRESCRIBED ERYTHROPOIESIS-STIMULATING AGENT 58
IRON 58
GLUCOSE MANAGEMENT 59
TABLE 24 COMMONLY PRESCRIBED GLUCOSE MANAGEMENT DRUGS 60
TABLE 24 (CONTINUED) 61
OTHER 61
TABLE 25 OTHER COMMONLY PRESCRIBED DRUGS 61
TABLE 25 (CONTINUED) 62
HORMONES 62
ACTIVE VITAMIN D 62
CALCIUM-LOWERING DRUGS 62
ADDITIONAL MEDICATIONS FOR DIALYSIS PATIENTS 63
Heparin 63
Citrate Anticoagulant 64
MEDICATIONS FOR CKD PATIENTS ON PD 64
INTRAPERITONEAL DOSING OF MEDICATIONS 64
DRUGS USED IN CONJUNCTION WITH KIDNEY TRANSPLANTATION 65
INDUCTION DRUGS 65
IMMUNOSUPPRESSANT AGENTS 66
TABLE 26 COMMONLY PRESCRIBED IMMUNOSUPPRESSANTS 67
TABLE 27 IMMUNOSUPPRESSION MAINTENANCE REGIMEN AT DISCHARGE AND 1 YEAR AFTER TRANSPLANT, 2006 68
TABLE 28 IMMUNOSUPPRESSION DRUG USE, INDUCTION DRUGS, AT DISCHARGE, AT 1 YEAR POST-TRANSPLANT, 2005 AND 2006 (%) 69
PHARMACEUTICALS USED IN ACUTE RENAL FAILURE 69
PHARMACEUTICALS USED IN CHRONIC RENAL FAILURE 70
TABLE 29 PREVALENCE OF HYPERTENSION AND DYSLIPIDEMIA BY CKD STAGE (%) 71
TABLE 30 AWARENESS, TREATMENT AND CONTROL OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES BY CKD STAGE (%) 71
TABLE 30 (CONTINUED) 72
COSTS 72
TABLE 31 COSTS OF COMMONLY USED PRESCRIPTION DRUGS FOR TREATING RENAL FAILURE AND ASSOCIATED DISEASES 73
TABLE 31 (CONTINUED) 74
THE U.S. MARKET FOR PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT 74
THE MARKET FOR MEDICATIONS TO TREAT DISEASES UNDERLYING CKD 75
THE MARKET FOR PHARMACEUTICALS USED IN ESRD TREATMENT FOR IN-CENTER DIALYSIS PATIENTS 75
CMS' New Bundled Dialysis Payment 76
THE MARKET FOR PHARMACEUTICALS USED FOR ESRD PATIENTS DIALYZING AT HOME 77
THE MARKET FOR PHARMACEUTICALS USED IN TREATING ARF 77
THE MARKET FOR PHARMACEUTICALS USED IN KIDNEY TRANSPLANTATION 78
TABLE 32 THE U.S. MARKET FOR PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2014 ($ MILLIONS) 79
FIGURE 14 THE U.S. MARKET FOR PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT BY TYPE, 1996-2014 ($ MILLIONS) 79
Chapter-7: RENAL RELACEMENT PRODUCTS AND THERAPIES USED IN KIDNEY FAILURE TREATMENT
HEMODIALYSIS 80
THE HEMODIALYSIS SYSTEM 80
TABLE 33 HEMODIALYSIS SYSTEM MARKET SHARE BY MAUFACTURER, 2009 (%) 81
FIGURE 15 HEMODIALYSIS SYSTEM MARKET BY MAUFACTURER, 2009 (%) 81
ACUTE CARE DIALYSIS EQUIPMENT 82
TABLE 34 THE CRRT SYSTEM MARKET BY MANUFACTURER, 2009 82
TABLE 35 DIALYSIS SYSTEMS AND MANUFACTURERS (HD, PD, CRRT) 83
DIALYZERS 83
TABLE 36 DIALYZER PRODUCTS, MANUFACTURERS, MATERIAL, AND TYPE 84
HEMOFILTERS 84
TABLE 37 HEMODIALYZERS, HEMOFILTERS MARKET SHARE, 2009 (%) 85
FIGURE 16 HEMODIALYZERS, HEMOFILTERS MARKET SHARE, 2009 (%) 85
MODES OF HEMODIALYSIS 86
Hemofiltration 86
Hemodiafiltration 86
Hemodiafiltration (Continued) 87
FIGURE 17 INTERMITTENT RENAL THERAPIES 88
MEASURING DIALYZER PERFORMANCE 89
DIALYZER REUSE 89
DIALYSATE 90
Sodium Citrate-Containing Dialysate 91
TABLE 38 DIALYSATE PRODUCTS FOR HD, PD, AND CRRT 91
TABLE 38 (CONTINUED) 92
TABLE 39 DIALYSATE MARKET BY MANUFACTURER RANK, 2009 92
DIALYSIS EQUIPMENT COSTS 92
TABLE 40 COSTS FOR COMMON DIALYSIS EQUIPMENT, HD, PD, CRRT ($) 93
THE U.S. MARKET FOR DIALYSIS SYSTEMS AND MAJOR CONSUMABLES 93
DIALYSIS MACHINES 93
TABLE 41 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, THROUGH 2014 ($ MILLION) 94
FIGURE 18 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, 1996-2014 ($ MILLION) 95
CONSUMABLES 95
TABLE 42 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, THROUGH 2014 ($ MILLION) 96
FIGURE 18 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, 1996-2014 ($ MILLION) 96
Dialyzers 96
Dialysate 97
PERITONEAL DIALYSIS 98
MODES OF PERITONEAL DIALYSIS 99
Continuous Ambulatory Peritoneal Dialysis 99
FIGURE 19 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 100
Continuous Cycler-Assisted Peritoneal Dialysis 100
Nocturnal Intermittent Peritoneal Dialysis 101
Tidal Peritoneal Dialysis 101
Dialysate for PD 102
PERITONEAL DIALYSIS EQUIPMENT MANUFACTURERS 102
TABLE 43 PERITONEAL DIALYSIS SYSTEMS, TYPE AND MANUFACTURER 102
TABLE 44 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY TYPE, 2009 (%) 103
FIGURE 20 PERITONEAL DIALYSIS EQUIPMENT MARKET BY TYPE, 2009 (%) 103
TABLE 45 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2009 (%) 104
FIGURE 21 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2009 (%) 104
CONTINUOUS RENAL REPLACEMENT THERAPIES 104
SCUF 105
CVVH 105
CVVHD 105
CVVHD (Continued) 106
FIGURE 22 CONTINUOUS RENAL THERAPIES (SCUF, CVVD, CVVHD) 107
CVVHDF 108
FIGURE 23 CONTINUOUS VENO-VENOUS HEMODIAFILTRATION 108
DIALYSIS SERVICES 109
TABLE 46 HEMODIALYSIS TREATMENT BY PROVIDER TYPE, 1990-2009 (%) 109
FIGURE 24 HEMODIALYSIS TREATMENT BY PROVIDER TYPE, 1990-2009 (%) 109
TABLE 47 U.S. DIALYSIS PROVIDERS, BY TYPE, 2008 110
TABLE 47 (CONTINUED) 111
TABLE 47 (CONTINUED) 112
TABLE 48 MARKET SHARE, HEMODIALYSIS PROVIDERS, 2009 (%) 112
FIGURE 25 MARKET SHARE, HEMODIALYSIS PROVIDERS (%) 113
THE U.S. MARKET FOR RENAL REPLACEMENT THERAPIES USED IN TREATING KIDNEY FAILURE 113
HEMODIALYSIS FOR TREATING CKD 113
Hemodialysis for Treating CKD (Continued) 114
RENAL REPLACEMENT THERAPIES FOR TREATING ARF 115
TABLE 49 THE U.S. MARKET FOR DIALYSIS THERAPY BY TYPE, THROUGH 2014 ($ MILLION) 115
FIGURE 26 THE U.S. MARKET FOR DIALYSIS THERAPY BY TYPE, 1996 TO 2014 ($ MILLION) 116
Chapter-8: SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT
VASCULAR ACCESS PROCEDURES 117
AV FISTULA 117
FIGURE 27 FOREARM AV FISTULA 118
AV GRAFT 118
FIGURE 28 A TYPE OF AV GRAFT 119
VENOUS CATHETER 119
FIGURE 29 VENOUS CATHETER 120
ACCESS REPLACEMENT/REPAIR 120
VASCULAR ACCESS MARKET BY TYPE 121
PERITONEAL DIALYSIS CATHETER 122
FIGURE 30 TENCKHOFF CATHETERS 122
PD CATHETERIZATION COSTS 122
KIDNEY TRANSPLANTATION 123
DECEASED DONORS 123
LIVING DONORS 123
THE TRANSPLANT PROCEDURE 124
Donor 124
Recipient 124
Compatibility 125
Post Surgery 125
THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN TREATING RENAL FAILURE 126
THE U.S. MARKET FOR SURGICAL ...(CONTINUED) 127
TABLE 50 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2014 ($ MILLION) 128
FIGURE 31 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, 1996-2014 ($ MILLION) 128
Chapter-9: THE INTERNATIONAL MARKET
CKD 129
ESRD 129
TABLE 51 GLOBAL INCIDENCE OF END-STAGE RENAL DISEASE, 2006 (PER MILLION POPULATION) 130
TABLE 51 (CONTINUED) 131
ESRD Treatment 131
TABLE 52 GLOBAL PATIENT DISTRIBUTION BY TYPE OF DIALYSIS, 2006 (%) 132
TABLE 53 GLOBAL TRANSPLANT RATES, 2006 (PER MILLION POPULATION) 133
TABLE 53 (CONTINUED) 134
ARF 134
MARKET 134
MARKET (CONTINUED) 135
Chapter-10: INDUSTRY STRUCTURE
TABLE 54 LEADING PRODUCT AND THERAPY PROVIDERS FOR RENAL FAILURE TREATMENT IN THE U.S., 2009 136
PHARMACEUTICALS MANUFACTURERS 137
DIALYSIS EQUIPMENT MAKERS 137
MANUFACTURERS OF DIALYSIS CONSUMABLES 138
THERAPIES 139
DIALYSIS 139
SURGERY 140
UNOS/OPTN 140
COMPANY PROFILES 141
ABBOTT LABORATORIES 141
AMAG PHARMACEUTICALS 141
AMERICAN REGENT INC. 142
AMERICAN RENAL ASSOCIATES, INC. (ARA) 143
AMERICAN VASCULAR DIALYSIS ACCESS CENTERS 143
AMGEN 143
ASAHI KASEI KURARAY MEDICAL CO. 144
ASTELLAS PHARMA U.S., INC. 145
ASTRAZENECA PLC 145
B.BRAUN MEDICAL INC. 146
BARD ACCESS SYSTEMS, INC. 146
BAYER HEALTHCARE 147
BAXTER INTERNATIONAL 147
BIOVAIL CORP. 148
BOEHRINGER INGELHEIM 149
BRISTOL MYERS SQUIBB COMPANY 149
CANTEL MEDICAL 150
CENTERS FOR DIALYSIS CARE 151
DAVITA, INC. 151
DIALYSIS CLINIC, INC. (DCI) 151
DIALYSIS CORP. OF AMERICA (DCA) 152
DIVERSIFIED SPECIALTY INSTITUTES (DSI) 152
ELI LILLY AND CO. 153
FOREST PHARMACEUTICALS 153
FRESENIUS GROUP 153
Fresenius Group (Continued) 154
Renal Solutions, Inc. 155
GAMBRO AB 155
GENENTECH INC. 156
GENZYME CORP. 156
GLAXOSMITHKLINE PLC 157
GREENFIELD HEALTH SYSTEMS 157
INNOVATIVE DIALYSIS SYSTEMS INC. (IDS) 158
JOHNSON & JOHNSON 158
KING PHARMACEUTICALS 159
KIDNEY CENTER, INC. 159
LIBERTY DIALYSIS 160
MAQUET CARDIOVASCULAR 160
MEDCOMP 161
MEDIGROUP INC. 161
MEDICINES CO. (THE) 162
MERCK & CO. 162
MYLAN BERTEK PHARMACEUTICALS 163
NAVILYST MEDICAL 163
NIPRO CORP. 164
NORTHWEST KIDNEY CENTERS 164
NOVARTIS PHARMACEUTICALS 165
NOVO NORDISK A/S 165
NXSTAGE MEDICAL 166
PAR PHARMACEUTICAL INC. 166
PFIZER 167
PROMETHEUS LABORATORIES INC. 167
REGIONAL RENAL RESEARCH INSTITUTE (RRI) 168
RENAL ADVANTAGE, INC. 169
RENAL VENTURES MANAGEMENT LLC 169
ROCHE (F. HOFFMANN-LA ROCHE LTD.) 170
ROCKWELL MEDICAL TECHNOLOGIES 170
SANOFI-AVENTIS 171
SATELLITE HEALTHCARE/WELLBOUND 171
SHIRE PHARMACEUTICALS GROUP 172
SIGMA-TAU PHARMACEUTICALS 172
SOLVAY PHARMACETICALS, INC. 173
TAKEDA PHARMACEUTICALS 173
TERUMO CORP. 174
TEVA PHARMACEUTICALS USA 174
TORAY INDUSTRIES, INC. 175
TRANSVIVO 175
UCB 176
U.S. RENAL CARE, INC. (USRC) 176
VASCULAR ACCESS CENTERS 177
WAKE FOREST UNIVERSITY OUTPATIENT DIALYSIS 177
WATSON PHARMACEUTICALS 178
WYETH 178
XCORPOREAL, INC. 179
APPENDIX 180
TABLE 55 TOP 50 U.S. HOSPITALS FOR RENAL DISORDERS 180
TABLE 55 (CONTINUED) 181
TABLE 56 U.S. KIDNEY TRANSPLANT CENTERS, 2006 181
TABLE 56 (CONTINUED) 182
TABLE 56 (CONTINUED) 183
TABLE 56 (CONTINUED) 184
TABLE 56 (CONTINUED) 185
TABLE 56 (CONTINUED) 186
TABLE 56 (CONTINUED) 187
To order this report:
Therapy Industry: Renal Disease Treatments: Products and Therapies
More Market Research Report
Nicolas BombourgReportlinkerEmail: [email protected]: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
